Navigation Links
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
Date:1/19/2011

, as we believe they significantly advance our understanding of the critical role endothelial cells play in inhibiting many of the aggressive aspects of cancer," stated Dr. Edelman, who is one of the original founders of Pervasis and a current member of the company's Board of Directors. "We believe this research will open the door to vast horizons for future research and the development of novel therapies, and we look forward to the work Pervasis is undertaking to advance these concepts to the clinical stage."PVS-30200 – Advantages over Current Cancer TherapiesMany current approaches to treating cancer are plagued by significant limitations such as high toxicity and serious side effects, and are systemic in nature, unable to locally target tumors. In addition, despite addressing the primary tumor, metastasis remains one of the most challenging aspects of treating cancer, and is a process that is often unpreventable and uncontrollable.  

PVS-30200 utilizes Pervasis' proprietary implantable material comprised of healthy allogeneic endothelial cells embedded in a polymer matrix that is delivered locally at the time of tumor excision to prevent cell-proliferation, inflammation and angiogenesis, key processes that lead to tumor growth and survival. The well-studied patented technology on which PVS-30200 is founded has a proven safety profile, as demonstrated by data from six clinical studies, and can be administered and targeted locally at the site of the tumor. A novel cell therapy approach, PVS-30200's use of allogeneic cells, as opposed to autologous cells, enables "off the shelf" administration, eliminating the challenging logistical processes that are involved with the use of autologous cells.  

"We plan to present our preclinical findings as well as the PVS-30200 technology to the oncology community as soon as possible; we believe this therapy has the potential to dramatically advance the promise of cell therapy as an innovative and v
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
3. PTC Therapeutics President and CEO Elected AAAS Fellow
4. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
5. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
6. Echo Therapeutics to Present at the OneMedForum 2011 Conference
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
9. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today ... Board of Directors, effective September 15, 2014. Dr. Raths, ... as its placement agent to market a private preferred ... and early stroke treatment. "Jurgen,s deep experience ... be a great asset to Vesselon as we develop ...
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
... May 10 Par Pharmaceutical Companies, Inc. (NYSE: ... Generics Limited and Glenmark Generics Inc., USA , has ... that resolves patent litigation related to Glenmark,s challenge to Merck,s ... involving a challenge by Glenmark which sought to launch a ...
Cached Medicine Technology:CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
(Date:9/23/2014)... with its advances promises of individualized genetic information ... Genetic tests are already guiding treatments of ... virus (HPC), and emerging research is showing genetic ... individual,s susceptibility to addiction to a substance, and ... appear to be many benefits inherent in the ...
(Date:9/23/2014)... Washington, DC (PRWEB) September 23, 2014 ... affordable care? The National Quality Forum (NQF) ... sheet ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( ... the rising cost of healthcare, how patients define ... for consumers to get the best possible healthcare ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... revealed that women do not put on weight as a ... center said that the belief weight is gained as a ... such beliefs// are not based on facts. ... over the past few years that examined the effects of ...
... predisposed where smoking is concerned, according to a new research. ... habit. A gene which is called CYP2A6 serves to regulate ... for smoking addiction. ,People carry different forms ... particular parts of the world, and the Asiatic people show ...
... in the functioning of the heart with the progress of age ... according to a study which the Journal of the American College ... goes to show that primary aging can // be delayed by ... ,This fact has already been proved in the ...
... A DNA study conducted at the burial pits of ancient ... large-scale devastation to the city. The Golden Age of Athens ... this // epidemic, which is said to have wiped out ... epidemic was in Ethiopia, between 430-426 BC, which later spread ...
... dish ‘Haggis’ had an increased fat diet which the officials ... are now facing a high risk of getting obese and ... Haggis not more than once in a week. ... liver and heart of sheep which is mixed with oatmeal ...
... herbs along with conventional medical treatment for severe acute respiratory ... life// of such victims, according to latest reports. It may ... margin. ,The researchers of the present study ... of 654 SARS patients, treated with both allopathic and Chinese ...
Cached Medicine News: